News

Parkinson’s Disease Phenotypes in Patient Neuronal Cultures and Brain Organoids Improved by 2-Hydroxypropyl-β-Cyclodextrin Treatment See our latest Publication Background The…

Together with colleagues from the Luxembourg Institute of Health (LIH) we were able to show that SARS-CoV2 can infect cells…

Fit 4 Start is an acceleration programme dedicated to high potential start-ups operating in the fields of Information and communications…

OrganoTherapeutics won the Rising Startup competition at Biovaria 2021 BioVaria Startup Awards go to iRASP Therapeutics and OrganoTherapeutics 30 April…

OrganoTherapeutics received support from the Luxembourgish Ministry of Economy for the project “Drug repurposing to target SARS-CoV-2 brain infection”. In…

We are very proud to annouce that our human midbrain organoid technology was selected for the SLAS 2021 New Product…

The article “Integrated, automated maintenance, expansion and differentiation of 2D and 3D patient-derived cellular models for high throughput drug screening”…

OrganoTherapeutics is very happy to announce that we have been selected as participants in the Luxembourgish Fit4Start program. The selection…

We are very happy to announce that OrganoTherapeutics has been accepted into the Creative Destruction Lab (CDL) program (https://www.linkedin.com/company/creative-destruction-lab/). We…

Today a new study with the title “Finding new treatment targets in Parkinson’s using a patient-based model of RNA mis-splicing”…